Prediction of Drug Response and Safety in Clinical Practice

[1]  Pei Wang,et al.  A targeted proteomics–based pipeline for verification of biomarkers in plasma , 2011, Nature Biotechnology.

[2]  Timothy J Kropp,et al.  Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. , 2011, Regulatory toxicology and pharmacology : RTP.

[3]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[4]  Richard M Weinshilboum,et al.  Genomics and drug response. , 2011, The New England journal of medicine.

[5]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[6]  P. Watkins,et al.  The Application of Metabonomics to Predict Drug‐Induced Liver Injury , 2010, Clinical pharmacology and therapeutics.

[7]  Yu Qin,et al.  Beta(2)-adrenergic receptor haplotype/polymorphisms and asthma susceptibility and clinical phenotype in a Chinese Han population. , 2010, Allergy and asthma proceedings.

[8]  A. Mehdipour,et al.  The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. , 2010, Clinical therapeutics.

[9]  D. Hochstrasser,et al.  The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone , 2010, British journal of pharmacology.

[10]  M. Wagner,et al.  A Phenotype–Genotype Approach to Predicting CYP450 and P‐Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir , 2010, Clinical pharmacology and therapeutics.

[11]  E. Amir,et al.  Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis , 2010, Breast Cancer Research and Treatment.

[12]  D. Herrington,et al.  Pharmacogenomics--10 years of progress: a cardiovascular perspective. , 2010, Pharmacogenomics.

[13]  S. Preskorn,et al.  Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. , 2010, The Journal of clinical psychiatry.

[14]  Richard S Paules,et al.  Use of transcriptomics in understanding mechanisms of drug-induced toxicity. , 2010, Pharmacogenomics.

[15]  R. Beger,et al.  Study of valproic acid-induced endogenous and exogenous metabolite alterations using LC-MS-based metabolomics. , 2010, Bioanalysis.

[16]  R. Plumb,et al.  A rapid ultra-performance liquid chromatography/tandem mass spectrometric methodology for the in vitro analysis of Pooled and Cocktail cytochrome P450 assays. , 2010, Rapid communications in mass spectrometry : RCM.

[17]  X. Boulenc,et al.  Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. , 2009, British journal of clinical pharmacology.

[18]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[19]  Y. Sugiyama,et al.  Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.

[20]  J. Lötsch,et al.  A Common Human μ-Opioid Receptor Genetic Variant Diminishes the Receptor Signaling Efficacy in Brain Regions Processing the Sensory Information of Pain* , 2009, Journal of Biological Chemistry.

[21]  J. Idle,et al.  Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. , 2009, Chemical research in toxicology.

[22]  D. Hochstrasser,et al.  The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction , 2009, The Pharmacogenomics Journal.

[23]  B. Carleton,et al.  Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Case–Control Study , 2009, Clinical pharmacology and therapeutics.

[24]  L. Kroon.  Drug interactions with smoking. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[25]  A. Gaedigk,et al.  Identification and Characterization of CYP2D6*56B, an Allele Associated with the Poor Metabolizer Phenotype , 2007, Clinical pharmacology and therapeutics.

[26]  Gavin Brooks,et al.  The use of proteomics to identify novel therapeutic targets for the treatment of disease , 2007, The Journal of pharmacy and pharmacology.

[27]  U. Fuhr,et al.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping , 2007, European Journal of Clinical Pharmacology.

[28]  U. Fuhr,et al.  Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the “Cocktail” Approach , 2007, Clinical pharmacology and therapeutics.

[29]  Christoph Plass,et al.  Toward a human epigenome , 2006, Nature Genetics.

[30]  S. Schappert,et al.  Medication therapy in ambulatory medical care: United States, 2003-04. , 2006, Vital and health statistics. Series 13, Data from the National Health Survey.

[31]  Gideon Koren,et al.  Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother , 2006, The Lancet.

[32]  Y. Daali,et al.  Codeine intoxication associated with ultrarapid CYP2D6 metabolism. , 2004, The New England journal of medicine.

[33]  D. Nebert,et al.  Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. , 2004, European journal of pharmacology.

[34]  C. Meisel,et al.  Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics , 2004, Clinical pharmacology and therapeutics.

[35]  S. Higuchi,et al.  A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. , 2004, Pharmacopsychiatry.

[36]  G. Tucker,et al.  A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. , 2003, British journal of clinical pharmacology.

[37]  N. Kurata,et al.  How useful is the ‘cocktail approach’ for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? , 2003, Journal of clinical pharmacy and therapeutics.

[38]  Michael Böhm,et al.  Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects , 2002, Clinical pharmacology and therapeutics.

[39]  A. Gaedigk,et al.  Unique CYP2D6 activity distribution and genotype‐phenotype discordance in black Americans , 2002, Clinical pharmacology and therapeutics.

[40]  P. Mayo.  Effect of Passive Smoking on Theophylline Clearance in Children , 2001, Therapeutic drug monitoring.

[41]  D W Nebert,et al.  Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. , 2000, European journal of pharmacology.

[42]  N. Benowitz,et al.  Drug Interactions with Tobacco Smoking , 1999, Clinical pharmacokinetics.

[43]  Jeffrey R Schein,et al.  Cigarette Smoking and Clinically Significant Drug Interactions , 1995, The Annals of pharmacotherapy.

[44]  M. Relling,et al.  Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. , 1991, Pharmacogenetics.

[45]  D. Grant,et al.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. , 1990, DNA and cell biology.

[46]  M. Karol,et al.  Effects of passive smoking on theophylline clearance , 1989, Clinical pharmacology and therapeutics.

[47]  N. Benowitz,et al.  Cigarette abstinence, nicotine gum, and theophylline disposition. , 1987, Annals of internal medicine.

[48]  W. Jusko,et al.  Effects of tobacco smoking and oral contraceptive use on theophylline disposition. , 1983, British journal of clinical pharmacology.

[49]  V. McKusick,et al.  Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.

[50]  T. Yamoto,et al.  A 1H NMR-based metabolomics approach for mechanistic insight into acetaminophen-induced hepatotoxicity. , 2011, Drug metabolism and pharmacokinetics.

[51]  P. Pávek,et al.  Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. , 2010, Methods in molecular biology.

[52]  S. Krähenbühl,et al.  Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone , 2010, European Journal of Clinical Pharmacology.

[53]  M. Murray,et al.  Pharmacogenetics of phase I and phase II drug metabolism. , 2010, Current pharmaceutical design.

[54]  Kuo-Chen Chou,et al.  Structure of cytochrome p450s and personalized drug. , 2009, Current medicinal chemistry.

[55]  I. Lacreuse,et al.  Conflict of Interest: None , 2009 .

[56]  Shufeng Zhou.  Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.

[57]  Ge Zhang,et al.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. , 2008, Drug metabolism reviews.

[58]  A. Daly,et al.  Individualized drug therapy. , 2007, Current opinion in drug discovery & development.

[59]  J. Lötsch,et al.  Genetic Predictors of the Clinical Response to Opioid Analgesics , 2004, Clinical pharmacokinetics.

[60]  D. Nebert,et al.  Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. , 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.